Andrew Rutter is a consultant specialising in Advanced Manufacturing Technologies, and the economics of supply chains. He is currently advising leading Pharmaceutical companies to accelerate their programmes to adopt technologies like Continuous Manufacture.

Over 20 years, he led the implementation of GSK’s Continuous Manufacturing and Modularisation programme, which culminated in the approval of 2 multistage API processes for NCE’s. This programme also explored applying modularised systems for large molecules, including vaccines and oligonucleotides.

He also was a member of the expert working group for ICH Q13 (Continuous Manufacturing Guidelines) representing EFPIA.

Title of presentation:

What would Hephaestus Build? Have 2 Years of a Pandemic and Emerging Climate Emergency accelerated or changed the imperative to improve the Supply of Medicines?